Metabolic Longevity: Do Anti-Aging Drugs & Supplements Actually Help Weight and Metabolism?

The same wellness channels that sell GLP-1s also sell an ever-growing shelf of "metabolic longevity" drugs and supplements — metformin, berberine, NAD precursors (NMN/NR), rapamycin, and senolytics — often implying they are gentler, natural, or more "root-cause" alternatives for weight and metabolic health. Some have real (if modest) data. Several have essentially none for weight. This hub ranks them honestly by the strength of human evidence for weight and metabolic outcomes, and links each to our fully-cited deep-dive. The short version: for actual weight loss, GLP-1 receptor agonists are the only category with large randomized proof — everything else here is adjunct, oversold, or still experimental.

The metabolic-longevity landscape, ranked by evidence

Proven: GLP-1 receptor agonists

Only one category on this list has large randomized trials showing meaningful, durable weight loss: the GLP-1 (and GLP-1/GIP) receptor agonists. Once-weekly semaglutide drove about 14.9% average weight loss over 68 weeks in STEP-1^[1], and tirzepatide reached about 20.9% in SURMOUNT-1^[2]. That is the benchmark every "longevity alternative" is implicitly measured against — and none of the others come close for weight. If weight loss is the goal, start with our provider rankings, not the supplement shelf.

Modest but real: metformin

Metformin is a genuinely useful metabolic drug — first-line for type 2 diabetes, improves insulin sensitivity, and produces a modest weight effect (typically a few kilograms). It is a reasonable adjunct, especially in insulin resistance or PCOS, but it is not an obesity drug and does not approach GLP-1 magnitude. Our metformin vs GLP-1 comparison and stacking evidence lay out where it fits.

Oversold or unproven for weight: berberine, NAD, rapamycin, senolytics

Berberine earned the "nature's Ozempic" label on social media, but the human data shows only small effects far below GLP-1s (the evidence). NAD precursors (NMN, NR) have no human weight-loss evidence and weak metabolic data despite the longevity marketing (NAD vs NMN vs NR). Rapamycin has landmark animal longevity data but zero human weight-loss trials — and chronic dosing can actually worsen blood sugar and lipids (rapamycin evidence). Senolytics are an exciting research area, but the metabolic benefit is a mouse finding; the human trials so far are tiny safety pilots in kidney and lung disease, and none measured weight (senolytics evidence). Marketed as weight or metabolic treatments in humans, these last two are experimental and off-label.